GlassScriptPhysician profile
Madhavi Reddy
NPI 1467565499
$42,887.48
in general payments reported to CMS, 2019-2025
32 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $215 · 2021: $821 · 2022: $13K · 2023: $8,723 · 2024: $9,019 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $6,125 · Travel and Lodging: $1,009 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,750.00 |
| Food and Beverage | $6,125.30 |
| Travel and Lodging | $1,009.30 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,803.99 | 2019-2025 | |
| Madrigal Pharmaceuticals | $1,217.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $1,142.04 | 2019-2025 | |
| Janssen Biotech, INC. | $526.78 | 2022-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $373.38 | 2019-2024 | Captivator II, Resolution 360 Clip, Endovive Low Profile Replacement Button |
| Celltrion USA INC. | $221.58 | 2025 | Zymfentra, Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $209.88 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Daiichi Sankyo INC. | $205.68 | 2019-2023 | Injectafer |
| Mirum Pharmaceuticals, INC. | $150.00 | 2025 | Livmarli |
| Celgene Corporation | $114.84 | 2022-2024 | Zeposia |
| Shire North American Group INC | $107.71 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $100.81 | 2024 | Fujifilm |
| Pfizer INC. | $87.50 | 2025 | |
| Glaxosmithkline, LLC. | $84.11 | 2025 | |
| Olympus America INC. | $52.09 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.17 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $47.34 | 2021-2022 | |
| Steris Corporation | $45.56 | 2020 | |
| Medtronic, INC. | $40.44 | 2023-2024 | Eleview, Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.10 | 2024 | Cyltezo |
| Novo Nordisk INC | $28.01 | 2024 | Rybelsus, Ozempic |
| Amgen INC. | $27.78 | 2025 | Uplizna |
| Braintree Laboratories, INC. | $26.40 | 2024 | Suflave, Sutab |
| Exact Sciences Corporation | $24.41 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.89 | 2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $23.68 | 2023 | |
| Covidien LP | $23.41 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $21.31 | 2024 | Eyemax, Lockado |
| Otsuka America Pharmaceutical, INC. | $21.26 | 2019 | |
| Exelixis INC. | $19.53 | 2022 | |
| Intra-Sana Laboratories | $19.05 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Avanos Medical | $13.29 | 2023 | Initial Placement Kits |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.